Answers are grounded in this paper and cite their sources.
Cutaneous malignant melanoma (CMM) remains one of the most aggressive and treatment-resistant skin malignancies, characterized by an exceptionally high propensity for early systemic dissemination and rapid metastatic spread. A pivotal milestone in melanoma progression is the “angiogenic switch,” a complex biological transition that marks the shift from an avascular radial growth phase (RGP) to a highly vascularized, invasive vertical growth phase (VGP). During this vertical expansion, primary tumor cells overcome metabolic and spatial constraints by fundamentally rewiring local vascular networks. Beyond classic sprouting angiogenesis driven by endothelial cell proliferation, highly aggressive melanoma cells exhibit remarkable lineage plasticity through Vasculogenic Mimicry (VM). In VM, plastic melanoma cells acquire endothelial-like features and de novo organize into extracellular matrix-rich, fluid-conducting tubular networks independent of host endothelial cells, establishing an alternative blood supply that sustains tumor growth and fosters anti-angiogenic drug resistance. At the intracellular level, the rapid expansion of melanoma lesions generates chronic hypoxia, nutrient deprivation, and metabolic stress, triggering severe endoplasmic reticulum (ER) stress-response pathways. To evade apoptotic death, neoplastic cells hijack intracellular stress responses and unconventional protein secretion machinery—driven by critical gatekeepers such as the SEL1L adaptor subunit of ER-associated degradation (ERAD) E3 ubiquitin ligase (SEL1L) and transmembrane p24 trafficking protein 10 (TMED10)—that maintain proteostatic survival while actively sculpting a pro-angiogenic and immunosuppressive secretome. Concurrently, immunomodulatory developmental programs like homeobox D13 (HOXD13) are co-opted to coordinate pathological angiogenesis with an “immune-cold” microenvironmental phenotype, shielding the tumor from effective cytotoxic immune surveillance. Furthermore, melanoma progression relies on dynamic, reciprocal cross-talk with non-neoplastic stromal constituents within the tumor microenvironment (TME), encompassing mast cells, tumor-associated macrophages (TAMs), and repair-like Schwann cells. Intercepting key extracellular signaling axes—including the down-regulation of platelet-derived growth factor receptor α (PDGFRα) and the inhibition of the fibroblast growth factor 2 (FGF2)/FGF receptor (FGFR) pathway by long pentraxin-3 (PTX3)—offers a powerful therapeutic approach to reverse epithelial–mesenchymal transition (EMT) programs and disrupt stromal support. Deciphering these multi-faceted microenvironmental interactions, proteostatic adaptation mechanisms, and alternative vascularization strategies provides a robust framework for designing high-precision, multi-target combination therapies capable of overcoming acquired drug resistance and halting metastatic progression in advanced CMM.
No takes yet. Share an insight, caveat, or question.
Tamma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: